≥99% PURITY GUARANTEEDTHIRD-PARTY TESTEDSAME-DAY SHIPPING USACOA WITH EVERY ORDERFREE SHIPPING $200+

For research and educational purposes only. Not intended for human consumption.

Prostamax

Limited Research
Updated Dec 2025

KEDP Tetrapeptide | Prostate Bioregulator

InjectableOral
Did you know? You can to improve this page.
0.5-1mg
Once daily
Injectable
Subcutaneous: abdomen
10-20 days
Typical duration
2-8°C
Refrigerated

Overview

What is Prostamax?

Prostamax (Lys-Glu-Asp-Pro/KEDP) is a synthetic tetrapeptide bioregulator from the Khavinson peptide family that demonstrates prostate-specific tissue effects. Preclinical research shows anti-inflammatory and tissue-protective properties in chronic prostatitis models, with emerging interest in epigenetic chromatin regulation and anti-aging applications.

Key Benefits

Direct systemic delivery, optimal bioavailability for prostate tissue targeting, established preclinical protocols, anti-inflammatory and tissue-protective properties.

Mechanism of Action

Subcutaneous injection provides systemic circulation for tissue-specific bioregulation of prostate gland cells. Induces deheterochromatinization (chromatin relaxation) potentially reversing age-related gene silencing.

Molecular Information

487.5 Da
Weight
4
amino acids
Bioregulatory tetrapeptide
Type
Amino Acid Sequence:
Lys-Glu-Asp-Pro (KEDP)
* Synthetic Khavinson peptide bioregulator with prostate tissue specificity

Pharmacokinetics

Peak
Variable
Half-life
Variable
Cleared
Variable
100%50%0%0h6h12h18h24h
Peak
Half-life
Cleared
Preclinical data

Research Indications

Chronic Prostatitis

Preclinical studies show reduced inflammation markers including tissue swelling, vascular hyperemia, and lymphoid infiltration.

Anti-Sclerotic Effects

Prevention of sclerotic and atrophic processes in chronic inflammatory prostate conditions.

Tissue Regeneration

Enhanced proliferative and metabolic activity in prostate epithelial cells and fibroblasts.

Research Protocols

Disclaimer: Human clinical trial data limited. Dosing extrapolated from preclinical models. Contraindicated with active prostate malignancy.

GoalDoseFrequencyRoute
Prostate Health Support0.5-1mgOnce dailySubcutaneous
Anti-Aging Protocol0.75mgOnce daily for 10-20 daysSubcutaneous
Preclinical Reference20 μg/kgDaily for 15 daysIntramuscular

Timing: Morning administration recommended. Rotate injection sites.

Peptide Interactions

How to Reconstitute

Important: Always use bacteriostatic water (BAC). Sterile technique is essential.

1

Allow vial to reach room temperature

2

Clean vial top with alcohol

3

Add 2.0mL BAC water for 10mg/mL concentration

4

Inject slowly down side of vial

5

Gently swirl - do not shake

6

Store reconstituted at 2-8°C, use within 14 days

Dosing Calculator

Calculate your injection volume with visual dosing guide

FINAL CONCENTRATION
2.50mg/mL
Each milliliter contains 2.50 mg of peptide
VISUAL REFERENCE (RESEARCH USE ONLY)

To obtain 250 mcg from this solution:

Draw 0.10 mL=10 units

(1 mL = 100 units on any insulin syringe)

0102030405060708090100
00.10.20.30.40.50.60.70.80.91.0
0.10 mL
10 units

Draw to this mark for 250 mcg

This calculator is for research purposes only. Always verify calculations and consult protocols.

Quality Indicators

White lyophilized powder

White to off-white freeze-dried powder.

Clear reconstituted solution

Crystal clear with no particles.

Certificate of Analysis

Third-party testing showing 99%+ purity.

Discolored or clumped

Yellow, brown, or heavily clumped indicates degradation.

What to Expect

  • Week 1-2: Subtle improvements, reduced inflammation markers
  • Week 2-3: Enhanced tissue function based on animal studies
  • Week 3-4: Peak effects observed in preclinical protocols

Side Effects & Safety

Side Effects

  • Human clinical data limited - extrapolated from preclinical
  • Possible mild injection site reactions
  • Rare digestive discomfort or headache
  • Contraindicated with active prostate malignancy
  • Quality sourcing critical

When to Stop

  • Adverse effects
  • Any prostate abnormalities
  • As directed by provider

References

2 Studies

Chronic Aseptic Prostatitis Study (2013)

Rat model | 20 μg/kg IM | 45 days | Reduced inflammation, enhanced sexual activity

Prostamax reduced swelling, hyperemia, lymphoid infiltration. Efficacy surpassed Serenoa repens and animal prostate extracts.

Deheterochromatinization Study (2012)

Human cell cultures | Elderly subjects | Chromatin relaxation

KEDP induces deheterochromatinization potentially reversing age-related gene silencing.

View Study

Quick Start Guide

Typical Dose
0.5-1mg daily
How Often
Once daily
Where to Inject
SubQ: abdomen
Timing
Morning administration recommended
Effects Timeline
Effects: 2-4 weeks; Full protocol: 10-20 days
Storage
Refrigerate 2-8°C, use within 14 days
Cycle Length
10-20 days
Break Between
4-6 months between cycles

Research Disclaimer

Prostamax is sold for laboratory research purposes only and is not intended for human or animal consumption. The information provided on this page is compiled from published research, veterinary studies, and anecdotal reports for educational purposes. This content does not constitute medical advice, diagnosis, or treatment recommendations. Any research involving Prostamax must comply with all applicable local, state, and federal regulations. BioInfinity Lab makes no claims regarding the safety or efficacy of Prostamax for any purpose. Consult qualified professionals for any research applications.